Sweatman - Treatment of Arthritis Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

What are the 3 classes of treatment approaches to arthritis?

A
  • NSAID’s: treat pain, and provide anti-inflammatory action
  • Disease-modifying anti-rheumatic drugs (DMARD’s): admin either locally by injection into arthritic joints, or systemically to provide immune suppression of the inflammatory process
  • Biologicals: also DMARD’s, but target specific molecular epitopes, rather than broad spectrum effects classical DMARD’s
  • NOTE: both classical and biological DMARD’s can slow progression of disease process (NSAID’s can NOT)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

NSAID’s overview

A
  • Pts should take lowest effective dose for shortest duration needed to control symptoms
  • Analgesic, antipyretic, anti-inflammatory actions
    1. Reversible (except ASA) INH of COX (COX-1 is constitutive, COX-2 is inducible)
    2. Unintended INH of COX is reason for many of the chronic NSAID side effects
  • NO oral NSAID is consistently more effective than any other; different pts may respond to/tolerate different NSAID’s differently (pay attention to pt’s individual CV/GI risk, and max dose)
  • ASA in high doses is as effective as any o/NSAID, but may have more GI toxicity -> non-acetylated salicylates have less GI toxicity than ASA
  • All undergo extensive hepatic metabolism, and are eliminated mainly via urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are PG’s? Which one plays a role in inflammation?

A
  • PGD2: bronchoconstriction, sleep, Alzheimer’s
  • PGE2: pain, vasodilation, bronchoconstriction, cytoprotective, INFLAMMATORY CELL ACTIVATION, fever, mucus production, possible erectile dysfunc
  • PGF2alpha: vascular tone, repro physiology, bronchoconstriction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do NSAID’s relieve pain (molecularly)?

A
  • After tissue damage, mast and macros activated and some polys may be recruited -> TNF-alpha, IL-1B, IL-6, NO, bradykinin nerve growth factor (NGF) released and activate nociceptive receptor that transduces sensation of tissue damage to CNS
    1. Exert their algesic effects by acting directly on nociceptors or indiretly via release of other mediators, i.e., PROSTANOIDS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Compare the effects of the traditional NSAID’s vs. those of the COX-2-specific drugs.

A
  • Major marketing point for the COX-2-specific drugs was a lack of effect on platelet aggregation, and significantly reduced incidence of GI toxicity
    1. However, unanticipated adverse effects on CV system
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do NSAID’s vary according to structural class, COX specificity, and half-life? Provide some examples.

A
  • Structural class: belong to several different structural classes
  • COX specificity: vary from COX-1 specific drugs like Ketorolac to COX-neutral drugs like Ibuprofen and COX-2 selective drugs like Celecoxib and Etodolac
  • 1/2 life: vary from Diclofenac/Ketoprofen with short duration to Piroxicam with long duration
    1. Dosing rate for the drugs varies by agent, so some require multiple doses, and other only once-daily dosing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do chronic NSAID’s produce damage?

A
  • Direct chemical irritation -> damage to the gastric mucosa with ulceration and gastric bleeds possible
  • INH of the cyto-protective effects of PGI2 on the gastric mucosa (i.e., mucus secretion, bicarbonate release, and initiation of repair process in the underlying tissue)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the risk factors for GI AE’s with the NSAID’s?

A
  • Varies by individual patient based on the parameters in the attached table
  • Risk also varies by drug: recent meta-analysis showed that RR risk for upper GI events was lowest for COX-2 INH and Diclofenac, and highest for Ibuprofen and Naproxen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are some ways to reduce NSAID GI toxicity w/o adding drugs?

A
  • Use COX-2 agent or traditional one w/gastro-protection
  • Enteric coating (aspirin): reduces, but doesn’t eliminate toxicity
  • FDA recommends taking NSAID’s w/food or milk to avoid stomach upset, but there is NO data to support this -> may be more better to advocate taking them on empty stomach to achieve rapid onset and avoid “extra dose” bc pt expectations for relief not met (according to Dr. S)
  • Pts w/gastric ulcers may remain asymptomatic, but occult blood will be evident in stool -> blood loss can be sufficient to produce iron deficiency anemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are some ways to reduce NSAID GI toxicity by adding add’l drugs?

A
  • Misoprostol: prostaglandin analogue
  • H2 receptor antagonist
  • Proton pump inhibito__r: superior efficacy due to more complete acid suppression (NSAID + PPI as effective as COX-2 alone; COX-2 + PPI reduces risk of endoscopic gastric ulcers)
    1. Caveat: can alter efficacy of concurrent drugs that rely on stomach acidity for absorption
    2. Reports on CV AE’s in pts w/Clopidogrel and PPI’s
    3. Adverse toxicity/INC risk for comorbid conditions still possible w/adjunctive PPI’s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How are the effects of Celecoxib different than those shown here? Why do they INC CV risk?

A
  • Traditional NSAID: no net change in balance b/t TXA2 and PGI2
  • COX-2 INH (e.g., Celecoxib): production of prostacyclin significantly INH, but production of TXA2 is NOT -> shift toward more pro-thrombotic state
  • However, the real situation is much more complex than this bc both Diclofenac (activity similar to Celecoxib) and Ibuprofen (COX-neutral) at high doses INC risk of vascular events in recent study
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which high-dose NSAID is NOT associated with vascular events?

A

Naproxen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How can NSAID’s potentially modulate the CV-protective effect of ASA?

A
  • Potential for concurrent admin of NSAIDs to INH ability of low-dose ASA (MI prophylaxis) to reach its binding site on platelet and provide irreversible enzyme INH (remember: anuclear platelets cannot regenerate) -> competitive inhibtion
  • Because traditional NSAID action is reversible, there is potential for antiplatelet activity to be lost, and INC CV risk to occur
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do the NSAIDs affect the liver?

A
  • Significany contribution (10%) to overall incidence of liver toxicity, reflecting their widespread use
  • Overall incidence is low, however, except with the use of Sulindac
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How can the NSAIDs produce renal toxicity?

A
  • PGE2 and PGI2 play an important role in the micro-regulation of perfusion in renal tissue, especially in abnormal “stress” situations, where they help to maintain GFR (and renal bloodflow via vasodilation)
  • Can lead to diminished renal function, renal tissue damage (i.e., nephrotic syndrome), or even acute renal failure (higher risk when initiating therapy)
    1. Reduce renal clearance of concurrent drugs (e.g., lithium and MTX)
    2. Antagonize effects of uricosuric agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What routine pt monitoring should be done for folks on chronic NSAIDs?

A
  • LFT’s, serum creatinine/BUN, stool guaiac, CBC
  • NSAIDs very rarely (<1%) produce blood dyscrasias, incl hemolytic or aplastic anemia, pancytopenia, or thrombocytopenia
  • Chronic ASA therapy may also warrant monitoring of serum salicylate (esp. in situations of intentional drug overdose)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is salicylate poisoning?

A
  • Metabolic product of ASA (acetyl-salicylic acid) is capable of crossing BBB where it stimulates the medullary respiratory center -> RESPIRATORY ALKALOSIS
    1. Hyperventilation leads to dehydration and compensatory metabolic acidosis
  • Also disrupts intermediary metabolism -> uncoupling of oxphos + interruption of glucose and FA metabolism lead to METABOLIC ACIDOSIS
  • Cerebral and pulm edema (INC cap permeability) lead to CV collapse/death if pt not decontaminated
  • Altered platelet function prolongs prothrombin time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the Beers criteria for the NSAIDs?

A
  • Avoid chronic use unless other alternatives are not effective and patient can take gastro-protective agent (PPI or misoprostol)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How is Acetaminophen used to treat arthritis?

A
  • NOT NSAID bc NO ANTI-INFLAMMATORY activity
  • Exact mechanism unclear, but thought to produce analgesia and antipyretic actions via INH of COX-1 and 2 in the CNS
  • Usually taken orally, but IV form just approved
  • Toxicity: NO GI AE’s w/oral therapy, but N/V, constipation, and diarrhea w/IV admin
    1. Renal toxicity also a rare event
    2. Most associated w/hepatic failure due to metabolic production of highly reactive adduct (risk for (un)intentional overdose)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the current treatment practice for RA?

A
  • Progressive approach
  • Initially: DMARD like MTX + NSAID + CCS
  • Milder cases: HYDROXYCHLOROQUINE preferred due to lower toxicity
  • Post-tx failure: Etanercept, Infliximab, Adalimumab, Golimumab, or Certolizumab alone or + MTX
    1. Poor response to these may elicit switch to a different one, or trying out: Anakinra, Rituximab, or Toclizumab
  • Aggressive tx w/MTX and/or biologic agent results in longer disease-free remission, less joint destruction, and a better QOL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How is MTX used to treat RA?

A
  • MOA: DHFR inhibitor, denying the cell essential methionine + INH cellular actions of adenosine via effects on adenosine deaminase and AMP deaminase enzymes
    1. INH lympho proliferation and suppresses secretion of IL-1, IFN-gamma, and TNF
    2. INC secretion of IL-4, impairs histamine release from basophils, DEC poly chemotaxis
  • Polyglutamated, helping to retain it in the cell
  • Bone marrow suppression (leukopenia, anemia, thrombocytopenia) at HIGH DOSES
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the potential MTX AE’s when treating RA?

A
  • Hepatic metabolism: contraindicated w/alcoholism or hepatic disease (enterohepatic recirculation)
  • 1o elim via kidney, so caution in renal failure (H2O and alkalinization reduce damage)
  • INC likelihood of opportunistic infection & bleeding
  • Avoid vaccines bc Ab response is suboptimal
  • Malignant lymphomas, severe (occasionally fatal) dermatologic rxns, and severe GI toxicity possible (esp. w/NSAIDs)
  • Potentially fatal or acute chronic interstitial pneumonitis, pulm fibrosis may not be reversible
  • Category X drug: contra in breast feeding
23
Q

What is Sulfasalazine?

A
  • Metabolized to sulfapyradine (a sulfonamide) and mesalamine (5-aminosalicylic acid) by colon bacteria
    1. Sulfapyradine acetylated/hydroxylated in liver, so poor acetylators have INC serum level
  • Beneficial effect from anti-inflam properties of mesalamine -> INH of PG and LT production
  • Renal excretion: dysfunction leads to accumulation w/repeated dosing
  • Contra w/PMH of hypersensitivity to salicylate or sulfonamide drugs
  • Potentially fatal blood dyscrasias infrequent
24
Q

What is Leflunomide?

A
  • CYP-produced metabolite INH dihydroorotate dehydrogenase (DHODH), a mito enzyme that catalyzes a key step in de novo pyrimidine synthesis (like MTX)
  • Cell cycle arrrest in T and B-cells: DEC lympho proliferation & Ig production suppressed
  • Uricosuric effect from metabolite: INC renal elim of uric acid
  • Elevated LFT’s with chronic use: caution advised in alcoholics, or w/heavy alcohol use
  • Not used w/immune suppression or infection
  • Category X drug
  • NOTE: CYP activity in plasma/intestinal mucosa
25
Q

What is Hydroxycholoquine?

A
  • Used for malaria, RA, and SLE
  • INC IC vacuole pH: acidity needed for Ag protein digestion and peptide assembly w/alpha and beta chains of MHC Class II proteins
    1. Failure to stimulate CD4+ T-cells -> down-regulation of immune response against auto-antigenic peptides
  • Drug concentrates in liver; may produce toxicity
    1. Caution w/hepatic disease/alcoholism
    2. Extensive/slow renal elim
  • Blood dyscrasias and CNS toxicity: polyneuritis, ototoxicity, seizures, or neuromyopathy
  • Rarely causes corneal opacities, keratopathy, or retinopathy -> contra in ocular disease
26
Q

What are the monitoring parameters for the 4 classic DMARDs for RA (table)?

A
  • Things that are different:
    1. MTX: serum uric acid
    2. MTX + Sulfa: serum creatinine/BUN
    3. Leflu: pregnancy test, serum electrolytes
    4. Hydro: opthalmologic exam
27
Q

Once again, what are CCS? How are they used to treat RA?

A
  • Most potent class of anti-inflammatory agents
  • Beneficial/AE’s related to transcriptional regulation:
    1. NFkB, AP-1, & NFAT INH -> DEC TNF, IL-1, IL-6
    2. Upregulation of receptor activator of nuclear factor B, aka RANKL and MCF
    3. Non-genomic mechs: Src INH, intercalation into plasma/mito membranes
  • Suppress signs/symptoms of RA, and also may have disease-modifying effects, at least in early-stage disease
28
Q

How does long-term tx with CCS give rise to glucocorticoid-induced osteoporosis?

A
  • Transient INC bone resorption in early tx due to stimulation of RANKL and MCF and downregulation of osteoprotegerin -> INC osteoclastogenesis and lifespan
  • Long-term: regulatory control of osteoblasts and osteocytes gives rise to DEC bone formation (CCS-induced osteoporosis)
    1. INC PPARy2 expression + DEC Wnt signaling = DEC osteoblastogenesis; activation of caspase 3 = INC osteoblast/cyte apoptosis
29
Q

What general preventive measures are used in RA pts treated with CCS?

A
  • Preventive measures:
    1. Lowest possible dose; reduce when possible
    2. Consider alternative admin routes/schedules
    3. Advise good nutrition: Ca, protein, Vit D (supplements, if needed)
    4. Recommend regular weight-bearing exercise
    5. Advise avoidance of tobacco/alcohol
    6. Assess risk of falls and advise accordingly
  • Treatment:
    1. Anti-osteoporotic therapy ASAP in pts at INC risk of bone fracture
    2. Continue anti-osteoporotic tx as long as CCS dose above intervention thresholds or fracture risk is INC
  • Monitoring:
    1. Assess adherence to therapy, incl dietary supplementation w/Ca and Vit D
    2. If vertebral fx suspected, assess by radiography or DXA
    3. Measure height annually and assess BMD at regular intervals (esp. if on high-dose regimen)
30
Q

What are some of the AE’s associated with long-term medium/high dose CCS use?

A
  • Only ones he noted were the adverse metabolic issues and the Cushingoid look, which can produce stark changes in physical appearance
31
Q

What “other AE’s” are associated with RA tx with CCS?

A
  • 2x risk of CV events when compared to gen pop
    1. Inflammatory condition
    2. Adverse drug effects: adverse lipid profile, blood glucose regulation, insulin production and resistance, obesity
    3. Severity of these effects for low-dose steroid tx remains to be established
  • Dose-dependent INC in risk of systemic infection
32
Q

What is one way to avoid the general systemic effects of the CCS?

A
  • Intra-articular injections provide local disease control and prevent widespread systematization of drug that occurs w/oral therapy
  • By selecting drug w/correct solubility characteristics, application site can function as a depot, releasing drug over extended period of time
    1. Most effective drugs are those w/limited solubility: Triamcinolone, Methylprednisolone
33
Q

What things should you monitor when using low-dose CCS to treat RA?

A
  • Pts on med/high dose need particular monitoring, but those on low dose need only std monitoring except for:
    1. Osteoporosis: concurrent use of bisphosphonates can mitigate risk
    2. Pre-tx fasting blood sugar levels
    3. Glaucoma risk
    4. Ankle edema
  • Adverse effects:
    1. Cumulative and daily dose dependent
    2. Co-admin of DMARD’s may INC risk
34
Q

What are the drug targets for the biologic RA drugs (image)?

A
35
Q

What are the MOA and mode of delivery for the biologic drugs for treating RA (table of 9)?

A
  • Many of these are MAb’s, others function as false receptors for circulating TNF (which exists in a soluble and transmembrane bound form)
36
Q

What are two potential AE’s associated with all of the RA biologics?

A
  • Immunosuppression results in INC susceptibility to bacterial, fungal, and parasitic infection
    1. Some BBW’s: DO NOT initiate tx in pt w/active infection
    2. UPPER RESP infections could be esp bad or occur more freq in asthmatics or COPD pts
    3. Advise pts to report signs/symptoms of infection or recurring infection (hep B, TB) during tx, and for several mos after stopping tx
    4. Advise to avoid live vaccines during tx
  • May INC likelihood of a malignancy
    1. Advise pt of INC risk of lymphoma and o/malignancies -> report persistent fevers, night sweats, or significant weight loss
    2. Malignancies have been reported with: Adalimumab, Certolizumab, Etanercept, Golimumabm and Infliximab (the anti-TNF’s)
37
Q

Which biologics cause CHF or hypotension/angina/dysrhythmia?

A
  • Adalimumab
  • Golimumab
  • Infliximab (moderate-severe heart failure is a contraindication for the use of Infliximab)
  • Rituximab
38
Q

What biologics cause a lupus-like syndrome (arthralgias, myalgias, fatigue, skin rashes)?

A
  • Adalimumab
  • Certolizumab
  • Etanercept
  • Infliximab
39
Q

What are two unique AE’s possible with Rituximab?

A
  • Stevens-Johnson syndrome: toxic epidermal necrolysis -> infrequently reported
  • Women taking Ritux must use reliable contraception while taking the drug, and avoid pregnancy for 4-6 months post-therapy
    1. IgG crosses placenta and could deplete B-cells
40
Q

Which biologic is in an IV solution containing maltose, which may complicate some blood glucose tests?

A

Abatecept

41
Q

Which biologics can cause blood dyscrasias?

A
  • Anakinra (IL-1)
  • Certolizumab (TNF)
  • Rituximab (CD20)
  • Tocilimumab (IL-6)
  • Routine CBC tests are advised
42
Q

Which biologics require LFT’s?

A
  • Golimumab (TNF)
  • Infliximab (TNF)
  • Tocilimumab (IL-6)
43
Q

Which biologic requires serum lipid profile testing?

A

Tocilimumab (IL-6)

44
Q

Which biologics require pt counseling regarding site rotation for SC self-administered drugs?

A
  • Abatacept (CTLA-4)
  • Adalimumab (TNF)
  • Anakinra (IL-1)
  • Certolizumab (TNF)
  • Etanercept (TNF)
  • Golimumab (TNF)
45
Q

What is Apremilast?

A
  • Drug that arrived on the market last year
  • Approval to treat psoriatic arthritis (improves joint tenderness, swelling) and plaque psoriasis (improves redness/scaliness)
  • Distinct MOA: orally active phosphodiesterase inhbitor (PDE4), giving rise to reduction in pro-inflammatory mediators
  • Oral drug: substrate of CYP3A4, 1A2, 2A6, and P-gp, w/extensive metabolism for renal/stool elim
  • Most common AE’s: nausea, headache, weight loss (monitor during tx)
    1. Rarely: depression, suicidal ideation (<1%; eval during routine office visits)
46
Q

What AE’s are associated with Adalimumab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • CHF or hypotension, angina, dysrhythmia
  • Lupus-like syndrome w/arthralgias, myalgias, fatigue, skin rashes
  • Pt counseling regarding site rotation for self-admin
47
Q

What are the potential AE’s with Infliximab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • CHF or hypotension, angina, dysrhythmia
  • Lupus-like syndrome w/arthralgias, myalgias, fatigue, skin rashes
  • LFT’s
48
Q

What are the potential AE’s with Golimumab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • CHF or hypotension, angina, dysrhythmia
  • LFT’s
  • Pt counseling regarding site rotation for self-admin
49
Q

What are the potential AE’s with Certolizumab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • Blood dyscrasias (CBC)
  • Lupus-like syndrome w/arthralgias, myalgias, fatigue, skin rashes
  • Pt counseling regarding site rotation for self-admin
50
Q

What are the potential AE’s with Toclizumab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • LFT’s
  • Serum lipid profile
51
Q

What are the potential AE’s with Etanercept?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • Lupus-like syndrome w/arthralgias, myalgias, fatigue, skin rashes
  • Pt counseling regarding site rotation for self-admin
52
Q

What are the potential AE’s with Anakinra?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • Blood dyscrasias (CBC)
  • Pt counseling regarding site rotation for self-admin
53
Q

What are the potential AE’s with Rituximab?

A
  • Immunosuppression: INC risk of infection
  • May INC likelihood of malignancy
  • CHF or hypotension, angina, dysrhythmia
  • Steven-Johnsons syndrome, or toxic epidermal necrosis (infrequent)
  • Reliable contraception while taking the drug, and need to avoid pregnancy 4-6 mos post-therapy (IgG crosses placenta and could deplete B-cells)
  • Blood dyscrasias